
[SPECIAL CONTENT] Fighting Against COVID-19
Fulfill Unmet Medical Needs (Priority Issue 1)
Targets for FY2030 | Major activities of FY2021 | Self- evalution |
---|---|---|
Develop and disseminate new treatments based on regenerative medicine and cell therapy |
|
〇 |
Improve Accessibilities to Medical Services (Priority Issue 2)
Targets for FY2030 | Major activities of FY2021 | Self- evalution |
---|---|---|
(1) Reducing burden on medical professionals by utilizing IT |
|
〇 |
(2) Development and dissemination of infectious disease diagnostic system to contribute to global health | ||
(3) Offering technical diagnosis training and spreading effective health practices to emerging countries | ||
(4) Improve medical accessibility by introducing our AI-driven products/services to all 196 countries/regions |
Contribute to Early Disease Detection (Priority Issue 3)
Targets for FY2030 | Major activities of FY2021 | Self- evalution |
---|---|---|
Reduce the physical burden through widespread and expanded use of medical diagnostic systems |
|
〇 |
Contribute to Health Promotion and Beauty (Priority Issue 4)
Targets for FY2030 | Major activities of FY2021 | Self- evalution |
---|---|---|
(1) Promote to prolong healthy lives |
|
〇 |
(2) Promote support for women’s empowerment |
Promote Management of a Healthy Workplace (Priority Issue 5)
Targets for FY2030 | Major activities of FY2020 | Self- evalution |
---|---|---|
Promote management of health and productivity to maintain employees’ vitality |
|
〇 |
Future Activities and Targets
As a company that supports the creation of cutting-edge therapeutic drugs, we will develop a "one-site one-stop" system that enables us to provide integrated contact development services from the process development to the formulation and final packaging of various biopharmaceuticals including antibody drugs and hormonal formulations, from small quantities to mass production. In addition, in order to contribute to the deterrence of the expansion of COVID-19, we will continue to provide a variety of medical equipment, including digital X-ray imaging device and ultrasound diagnostic equipment, and process development and contract manufacturing for vaccines and other products at pharmaceutical companies.
In the healthcare IT field, under the REiLI brand, we will develop and commercialize AI technologies that support the workflow of healthcare professionals, combining CT, MRI, X-ray diagnostic equipment, and a wide range of other modalities with IT technologies incorporating state-of-the-art AI systems.